HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Retatrutide phase 3 results: average 28% body weight loss in about 18 months

Louis Nervegna · May 22, 2026 · ♥ 5 reactions · 0 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Weight, visceral & liver fat
AI summary & key facts

Louis shares a CBS report on Eli Lilly's retatrutide, a not-yet-approved triple agonist drug, with an average 28% body weight loss (up to 70 lb) in around a year and a half in a large phase 3 trial. Details come from a news segment.

Huge phase 3 trial results on Eli Lilly’s new weight loss drug, retatrutide.

People lost 28% of their bodyweight on average (up to 70lbs), in around a year and a half.

#retatrutideHD #glp1HD #elilillyHD #gipHD #glucagonHD #weightlossHD

Research cited

Retatrutide, a new weight loss drug not available on the market yet, is showing promising results in trials. Dr. LaPook explains it’s doing much more than what current medications can.

← newer: Whole-blood NAD+ does not change with age or lifestyle, so iolder: Low genetic risk for coronary artery disease is linked to mu →